Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

BIOGEN ($BIIB) Releases Q1 2026 Earnings - Quiver Quantitative

📊 Biogen reported Q1 2026 earnings with EPS of $3.57, exceeding the analyst estimate of $3.07 by $0.50.

💵 Revenue reached $2.48 billion, surpassing the expected consensus of $2.30 billion by approximately $177 million.

📈 The company's stock performance on Quiver Quantitative includes data tracking insider trading and hedge fund activity.

👥 Insider trading shows 3 transactions in the last 6 months, consisting of 1 purchase and 2 sales.

🏦 Institutional investors saw net movement with 458 adding shares while 390 decreased positions in the most recent quarter.

⚖️ Congressional trading recorded 1 purchase by members of Congress over the past 6 months with no sales.

📝 Wall Street analyst sentiment includes 2 firms issuing buy ratings and 1 firm issuing sell ratings recently.

🎯 Price targets were set by 19 analysts in the last 6 months, with a median target price of $214.00.

⚠️ Readers are reminded that this content is not financial advice and may contain ticker-mapping inaccuracies.

🔗 Quiver Quantitative provides access to API data for tracking congressional trading, insider transactions, and hedge fund moves.

Bullish Signals
  • BIOGEN reported earnings of $3.57 per share, beating analyst estimates of $3.07 by $0.50 in Q1 2026.
  • Revenue reached $2,477,800,000, surpassing analyst estimates of $2,300,490,853 by $177,309,147.
  • Two Wall Street firms have issued buy ratings on the stock in addition to one sell rating, indicating mixed but favorable analyst sentiment.
  • A median price target of $214.0 has been established by 19 analysts in the last 6 months, suggesting upside potential.
  • Institutional investors added shares to their portfolios, with 458 firms increasing positions compared to 390 that decreased them.
Risk Factors
  • Despite beating earnings estimates by $0.50 per share, the company experienced a net outflow in institutional ownership with 390 investors decreasing their positions compared to 458 adding shares.
  • Insider trading data shows more selling than buying activity over the past six months, with insiders executing two sales against only one purchase of $BIIB stock.
  • Wall Street sentiment is mixed among analysts, with only 1 firm issuing a sell rating compared to 2 firms issuing buy ratings for the stock.
  • Analyst price target dispersion includes concerns as one sell rating contrasts with median price targets of $214.0, indicating some negative outlooks on future valuation.
Full Analysis
Biogen (NASDAQ: $BIIB) reported its first quarter 2026 earnings results on Wednesday, April 29th, delivering positive financial performance that exceeded market expectations. The pharmaceutical company posted an earnings per share of $3.57, surpassing the analyst consensus estimate of $3.07 by $0.50. Revenue for the quarter reached $2.477 billion, which beat the estimated revenue of $2.300 billion by approximately $177.3 million. These results indicate strong operational performance during the first three months of 2026. Following the earnings release, significant activity in insider and institutional trading was observed over the preceding six-month period. Biogen insiders executed three open market transactions involving the stock, consisting of one purchase and two sales. Institutional investor sentiment showed a net increase in holdings, with 458 investors adding shares to their portfolios compared to 390 investors decreasing their positions during the most recent quarter. Legislative involvement was minimal, with members of Congress trading the stock once in the last six months, specifically through one purchase transaction and no sales. Wall Street analyst coverage for Biogen reflects a generally positive outlook despite mixed ratings from individual firms. In total, 2 analysts issued buy ratings while 1 firm issued a sell rating over several months. Pricing guidance suggests potential growth, as 19 analysts provided price targets for the stock within the last six months, establishing a median target price of $214.00. Investors and market participants can continue to track detailed data regarding insider trading, hedge fund activity, congressional transactions, and analyst forecasts through Quiver Quantitative's dedicated dashboards and APIs.